Riboscience to Present Cancer Drug Data on October 24
The company will unveil Phase 1b clinical trial results for its ENPP1 inhibitor at the upcoming ESMO Congress 2026.
Updated on Oct. 20, 2026 in Cancer
Riboscience is set to present Phase 1b clinical study data for the oral ENPP1 inhibitor RBS2418 on October 24, 2026. This data will be shared during the ESMO Congress 2026, which is being held in Madrid, Spain.
Why it matters
The study targets ENPP1 expression in solid tumors, which is linked to immune evasion and a block of dendritic cell activation. By inhibiting ENPP1, the drug aims to restore anti-tumor immunity by preventing cGAMP clearance in the tumor microenvironment.
The Phase 1b study (NCT05270213) includes a safety population of 89 patients. The findings for RBS2418 will be formally presented under abstract/poster number 1977P.
The players
Riboscience
This is a biotech firm based in Palo Alto, California, that specializes in the development of targeted cancer therapies.
ESMO Congress 2026
This is an international professional medical gathering for oncology researchers and clinicians to review new clinical trial results.
The details
RBS2418 functions by binding to ENPP1 with picomolar affinity and high selectivity to prevent cGAMP degradation. Riboscience is evaluating the drug as both a monotherapy and in combination with other treatments for advanced unresectable, recurrent, or metastatic solid tumors.
Timeline
The ESMO Congress 2026 is scheduled for October 23-27, 2026, in Madrid, Spain.
Riboscience will present its study data on October 24, 2026.
The Big Picture
This development follows a pattern set by the STRIDE regimen, which leverages multi-drug combinations to improve cancer outcomes. Riboscience is testing RBS2418 alongside such regimens to further explore synergistic effects in hepatocellular carcinoma.
This study advances the pipeline for potential new treatment options for patients with advanced or metastatic solid tumors. While currently in clinical testing, these developments provide insight into emerging oral inhibitors that may eventually shift standard care protocols.
The takeaway
Patients and caregivers should note that these early-stage results are designed to evaluate the safety and initial response of new targeted therapies. Future phase trials will continue to determine if these inhibitors can provide meaningful clinical benefit for late-line cancer patients.
Further reading
For more information on the latest breakthroughs in clinical oncology, visit the Cancer section.
Source note: This article includes information reported by Pharma.
